Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| Eli Lilly and Company | NetApp | MediaTek | |
|---|---|---|---|
| Moat rating | wide Eli Lilly's FY2025 10-K states "Intellectual property protection is critical" and that compound patents provide roughly 20-year market exclusivity ("patents in each relevant country last for a period of 20 years"), warning that loss of patent protection causes a "severe and rapid decline in revenues." Backed by an 83.0% gross margin (up from 81.3% in 2024) and a fast-growing, patent-protected incretin franchise (Mounjaro +99%, Zepbound +175% in 2025), the economic moat is wide and durable. Source: LLY FY2025 10-K. | narrow The FY2026 10-K shows a real, durable lock but not an unassailable one. On the durable side: "Our cloud storage services are based on the same ONTAP data management software that underpins our on-premises ONTAP storage infrastructure offerings", and the same filing's income statement shows the company holding a gross margin near 71% across all three reported years - $4,433M on $6,268M in FY2024, $4,613M on $6,572M in FY2025 and $4,899M on $6,925M in FY2026 - while revenue grew from $6,268M to $6,925M and income from operations widened from 19% to 24% of net revenues. Holding that margin through the memory-cost shock the same filing discloses is the commercial evidence the lock is worth something. On the limiting side, the filing says competition "is intense", that in public cloud "customers may choose native cloud services that are consumed as operating expenses", and that "New competitors or alliances among existing competitors could emerge and quickly gain significant market share" - and IDC's 1Q26 external-storage tracker (Blocks & Files, 2026-06-16, cited on the AFF/ASA product row below) ranks NetApp second behind Dell, not first. | narrow Counterpoint's public quarterly AP-SoC table, published 8 September 2026, shows MediaTek first in all ten quarters it covers (Q1 2024 through Q2 2026), never below 31%, with the nearest rival never above 30% -- a sustained position, not one good quarter. What the same table does not show is a widening one: the share oscillates inside a 31% to 41% band, the Q1 readings step down 41% (2024), 38% (2025), 33% (2026), and the 31% of Q2 2026 matches the lows already set in Q4 2024 and Q4 2025 rather than breaking them; Q2-on-Q2 the series runs 34%, 36%, 31%. Counterpoint also records MediaTek's shipments down more than 30% year-over-year in the quarter, the mainstream and entry tiers hit by the memory shortage and the premium tier by a 'slowdown in sales of Dimensity 9000 series powered devices.' MediaTek's own 2Q26 remarks show the gross line holding and the operating line not: gross margin 46.2%, down only 0.1 percentage points sequentially and guided at 46% plus or minus 1.5 for Q3, while operating income fell 22.2% year-over-year on revenue up 1.2% as operating expenses rose to NT$47.4 billion from NT$44.5 billion. A first place held for ten quarters without extending it, and earning less on it, is defensible rather than compounding. |
| Moat type | intangibles ip Per the LLY FY2025 10-K, the pharma protection "anticipated to be of most relevance" is "patents claiming the active ingredient (the compound patent)," supplemented by regulatory data protection, FDA approvals, and brands — i.e., intangible assets. The 10-K notes that without such protection, products face intense generic and biosimilar price competition that erodes revenue quickly. | switching costs The FY2026 10-K makes the source of the advantage explicit and it is the cost of leaving the data-management layer, not a network or a patent estate. The same ONTAP software runs the on-premises arrays and the cloud services ("Our cloud storage services are based on the same ONTAP data management software that underpins our on-premises ONTAP storage infrastructure offerings"), and the AFF family "allows customers to connect to clouds for more data services, data tiering, caching, and disaster recovery". A customer's volume layout, snapshot and replication workflow and operating tools therefore carry from the array into Azure, AWS and Google rather than being abandoned at the cloud boundary — the filing describes NetApp as "the only provider of enterprise-grade storage services natively embedded in the world's largest public cloud providers", so the usual moment of escape is instead the moment the relationship renews. | intangibles ip MediaTek manufactures nothing itself -- its 2Q26 remarks describe 'deep design-technology co-optimization (DTCO) with TSMC' and close collaboration with advanced-packaging partners -- so the durable asset cannot be plant scale, and the remarks do not claim customer lock-in either. They locate it in a reusable design library: 'Building on our industry-leading IP portfolio, we offer best-in-class, pre-validated subsystems solutions for memory, I/O, and connectivity' -- which, the company says, 'largely reduces design complexity and shortens time to market for our data center customers'. The same remarks itemise 448G SerDes with a Co-Package Copper system solution, CPO development on TSMC's COUPE platform, and an end-to-end 3.5D platform with 'best-in-class 3.5D IP, packaging, and design flows,' and say design wins come 'backed by our industry-leading IPs, deep ecosystem partnerships, and proven execution capabilities'. The spending behind that library shows in the cost line: operating expenses of NT$47.4 billion in the quarter against NT$44.5 billion a year earlier, with the Q3 operating expense ratio guided at 31% plus or minus 2 points. It is the same library MediaTek re-amortises across mobile, edge and now data-center ASIC. |
| Leadership | co leader Duopoly with Novo Nordisk: Novo's own FY2025 20-F names "Novo Nordisk and Eli Lilly [as] the most significant companies measured by market share" in the global diabetes and GLP-1 markets. Lilly is ascendant — the 20-F concedes Wegovy's years-long US anti-obesity prescription lead "was overtaken by a competing GLP-1 based product in the beginning of 2025" (Lilly's tirzepatide) — but Novo still cites Ozempic as "the leading product by sales," so co-leader is the honest band. Sources: Novo Nordisk FY2025 20-F; LLY FY2025 10-K. | co leader IDC's 1Q26 external enterprise storage systems tracker, as reported by Blocks & Files on 2026-06-16 (cited in full on the AFF/ASA product row below), ranks NetApp second worldwide behind Dell and ahead of Everpure, Huawei and HPE, attributing the placing to "its growing all-flash business and cloud-integrated data management". Second of five ranked vendors, in a market whose leader is someone else, is a shared front rank rather than an owned one - and the distinct claim NetApp makes in the FY2026 10-K is positional rather than volumetric: being "the only provider of enterprise-grade storage services natively embedded in the world's largest public cloud providers". | co leader Counterpoint has MediaTek ahead of every rival in all ten quarters of its public table -- 31% against Qualcomm's 23% and Apple's 19% in Q2 2026 -- but that count covers smartphone application processors only, and MediaTek's 2Q26 remarks put mobile phone at 41% of group revenue, no longer its largest business. Smart Edge Platforms is larger at 53%, and while the remarks claim 'continued market share gains across connectivity, computing and automotive products', no independent count of those positions appears in the sources used here. In data center MediaTek holds nothing yet: production of its first AI accelerator ASIC is scheduled for the fourth quarter of 2026, and 15% to 20% is a 2027 target raised from 10% to 15% a quarter earlier. Inside its core market the flagship tier is a stated plan rather than a claimed position -- a 2nm SoC launching in the third quarter and, 'together with ongoing engagements with global players, we will increase our presence continuously in the flagship smartphone market in 2027' -- while Counterpoint records MediaTek's premium-tier shipments declining on a 'slowdown in sales of Dimensity 9000 series powered devices.' |
| Pricing power | moderate Mixed. The LLY 10-K shows an 83.0% gross margin (up 1.7pp), evidence of strong list-price power on exclusive branded drugs; but it repeatedly notes 2025 revenue growth was "partially offset by lower realized prices" for both Mounjaro and Zepbound, alongside heavy PBM/formulary rebate pressure and default anti-obesity coverage restrictions (e.g., US self-insured employers "must generally opt in" for obesity-drug coverage). Net pricing power is therefore moderate, not strong. | moderate It holds price rather than raising it. On the figures filed with the FY2026 10-K, gross margin was 70.7% of revenue in FY2024 ($4,433M on $6,268M), 70.2% in FY2025 ($4,613M on $6,572M) and 70.7% in FY2026 ($4,899M on $6,925M) - flat across three years in which revenue grew from $6,268M to $6,925M - and it held that level while absorbing a component-cost shock. It is no stronger than that because the filing's own risk factor lists "competitive pricing, customer price sensitivity" and "pricing and discounting pressures" among the drivers of gross margin, and discloses that the company "experienced inflationary pressure and supply chain constraints beginning in the second half of fiscal 2026, resulting in increased costs for memory and other components, which have affected our gross margins" - a cost shock it is absorbing rather than fully passing on. | moderate The 2Q26 remarks describe price as cost pass-through rather than capture: 'As rising costs across the supply chain have become an industry-wide reality, we are taking pricing actions to ensure these increases are appropriately reflected in our product pricing', with the full-year aim, 'through our disciplined pricing strategy', to 'deliver our full year gross margin within the current quarter guidance range' -- holding a band, not widening it. The realised figures show that defence working: gross margin 46.2%, down 0.1 percentage points sequentially, with Q3 guided at 46% plus or minus 1.5 points. The 2.9-point year-over-year decline is not an erosion rate; the company states it 'was mainly due to a one-time benefit in the year-ago quarter.' Holding a mid-40s gross margin through a market the company expects to decline 'by about 15% in units this year' is genuine discipline, but passing rising costs through to defend a guided band is not the ability to price above it. |
| Summary | Lilly's moat rests on patent-protected, FDA-approved branded medicines led by its tirzepatide incretin franchise: per the FY2025 10-K, Mounjaro ($22.97B) and Zepbound ($13.54B) together generated roughly 56% of 2025's $65.2B revenue (up 99% and 175% respectively), while compound patents confer ~20-year market exclusivity and support an 83.0% gross margin. Durable competition only emerges after patents and regulatory data protection lapse, at which point the 10-K warns generics and biosimilars drive a "severe and rapid decline in revenues." | NetApp sells storage hardware but the asset is ONTAP, the data-management software that has run its arrays for over three decades and now also runs inside the three largest public clouds as a first-party service. The FY2026 10-K organises the company into two segments, Hybrid Cloud (AFF and ASA all-flash arrays, AFX for AI workloads, FAS hybrid-flash, E/EF-Series, StorageGRID object storage) and Public Cloud (Azure NetApp Files, Amazon FSx for NetApp ONTAP, Google Cloud NetApp Volumes, Cloud Volumes ONTAP), and states that both rest on the same ONTAP software. That is the whole argument: an enterprise that has standardised its snapshots, replication and multiprotocol access on ONTAP carries those habits with it when it moves workloads to a hyperscaler, and NetApp is paid on both sides of the move. The evidence that the lock has commercial value is the margin's steadiness: across the three years the FY2026 10-K reports, gross margin sat at 70.7%, 70.2% and 70.7% of revenue ($4,433M on $6,268M, $4,613M on $6,572M, $4,899M on $6,925M) while revenue grew, and the filing's own percentage-of-revenue table shows no mix shift doing that work - product and services held near 46% and 54% of revenue throughout. The limits are equally in the filing. NetApp is second, not first: IDC's 1Q26 tracker puts it behind Dell in external enterprise storage, and the 10-K's competition section concedes that cloud providers are simultaneously partners and rivals, that consumption models "may reduce overall demand for our traditional on-premises offerings sold through a capital expenditure (capex) model", and that alternative architectures "may reduce or eliminate demand for some of our offerings". Component exposure is real too: the filing discloses "inflationary pressure and supply chain constraints beginning in the second half of fiscal 2026, resulting in increased costs for memory and other components, which have affected our gross margins", and names NAND among the components whose supply can tighten. This is a durable second place built on software stickiness, not a structural monopoly. | MediaTek is the largest supplier of smartphone application processors by units and has been for as long as Counterpoint's public quarterly table runs. Across all ten quarters it covers, Q1 2024 through Q2 2026, MediaTek is first every time and never below 31%, while the nearest rival never clears 30%; in Q2 2026 it holds 31% against Qualcomm's 23%, Apple's 19%, UNISOC's 13%, Samsung's 9% and HiSilicon's 5%. That is a real, independently counted position, and it is the only part of MediaTek's business for which such a count exists in the sources used here. The same table is the clearest evidence that the position is being defended rather than extended. MediaTek's share moves inside a 31% to 41% band across the ten quarters, and the top of that band has come down -- 41% in Q1 2024, 38% in Q1 2025, 33% in Q1 2026 -- while the 31% of Q2 2026 matches the lows already set in Q4 2024 and Q4 2025 rather than breaking them; measured like for like against the same quarter a year earlier the series runs 34%, 36%, 31%. Counterpoint records MediaTek's shipments falling more than 30% year-over-year in the quarter -- hit in the mainstream and entry tiers by the memory shortage, and in the premium tier by a slowdown in Dimensity 9000 series devices -- while Samsung's Exynos climbed to 9% on Galaxy S26 base variants and mid-tier A-series wins. MediaTek's own 2Q26 remarks show the gross line holding and the operating line not: gross margin of 46.2%, down 0.1 percentage points sequentially and guided at 46% plus or minus 1.5 for the third quarter, against operating income down 22.2% year-over-year on revenue up 1.2%, with operating expenses of NT$47.4 billion against NT$44.5 billion a year earlier. Unit leadership held while the return on it did not. What MediaTek re-uses is design IP. It manufactures nothing itself -- the remarks describe deep design-technology co-optimization with TSMC and close work with advanced-packaging partners -- and they locate the durable asset in a pre-validated library of memory, I/O and connectivity subsystems, 448G SerDes with a Co-Package Copper system solution, CPO development on TSMC's COUPE platform, and an end-to-end 3.5D platform. The spending behind that library is visible in the cost line: operating expenses of NT$47.4 billion in the quarter against NT$44.5 billion a year earlier, with the Q3 operating expense ratio guided at 31% plus or minus 2 points against a gross margin guided at 46% plus or minus 1.5 -- an operating cost base running near a third of revenue. That library is now pointed at two adjacencies. Smart Edge Platforms -- connectivity, computing, automotive and TV SoCs -- is now the larger business, at 53% of revenue in Q2 against mobile's 41%, and grew 26% year-over-year while mobile fell 20%. And the company says it has built its first AI accelerator ASIC for a major US cloud customer, with production scheduled for the fourth quarter of 2026. One adjacency is a target and one is a contribution, and this profile treats them as exactly that. The data center share figure of 15% to 20% is a 2027 target against a served market MediaTek itself sizes at US$80 billion, raised from 10% to 15% only one quarter earlier, and production of the first ASIC was still scheduled for the fourth quarter at the date of the remarks. The RTX Spark AI PC work is corroborated by NVIDIA's own announcement, which credits MediaTek with collaborating on the custom CPU design and contributing to its power efficiency, performance and connectivity -- but the superchip, its Grace CPU, its NVLink-C2C interconnect and its software stack are NVIDIA's, and the systems ship from PC makers, so what MediaTek holds is a design contribution rather than a franchise with a share to count. The claimed share gains in connectivity, computing and automotive carry no number and no third-party count. The honest reading is a company with one durable, independently verified franchise it is holding rather than extending, funding a credible but still unproven move into higher-value silicon on the strength of its IP portfolio. |
| Chain position | Upstream branded-drug originator. Per the FY2025 10-K, US distribution flows through three wholesalers (McKesson, Cencora, Cardinal Health), each accounting for over 10% of consolidated revenue, into consolidated PBMs/payers whose formularies and rebate demands constrain net price; Lilly is also expanding a direct-to-patient channel, LillyDirect. | NetApp sits between the memory supply and the enterprise data centre. Upstream, the FY2026 10-K says "Third-party component costs make up a significant portion of our product costs" and singles out NAND as hard to manage "if supplies of certain components, including NAND, become limited relative to demand". Downstream, the hyperscalers are channel, partner and rival at once: the filing states "We both partner with and compete against cloud service providers through our cloud-based software and services offerings", while Azure NetApp Files, Amazon FSx for NetApp ONTAP and Google Cloud NetApp Volumes are delivered as those clouds' own natively embedded services. Distribution is a mix of direct sales and "an ecosystem of partners, including the leading cloud providers". | A fabless designer sitting between its customers and the TSMC-centred manufacturing chain. The 2Q26 remarks describe 'deep design-technology co-optimization (DTCO) with TSMC' and close work with advanced-packaging partners to build 'high-performance ASICs across a broad range of very-large chip sizes using CoWoS and EMIB-T technologies' at nodes down to 2nm, and say MediaTek creates 'significant value beyond semiconductor by orchestrating other key components throughout the supply chain such as memory and substrate' -- a coordinator role as much as a design one. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.30 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. | +0.13 at weight 0.20 · swarm neutral Editorial prior, not backtested. |